Gara Jalqabaatti › Saree Oljoo › Connecticut › Bridgeport
Qorannoo klinikaalii Saree Oljoo Bridgeport, CT keessatti
Qorannoo 21 Saree Oljoo f Bridgeport fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Stony Brook University Medical Center, Stony Brook · Miili 18 fagaatti
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · Miili 18 fagaatti
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Stony Brook · Miili 18 fagaatti
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · Miili 4 fagaatti
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · Miili 5 fagaatti
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Stony Brook Cancer Center, Stony Brook · Miili 18 fagaatti
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Stony Brook University Hospital, Stony Brook · Miili 18 fagaatti
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Stony Brook University Medical Center, Stony Brook · Miili 18 fagaatti
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Stony Brook University Cancer Center, Stony Brook · Miili 18 fagaatti
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Namoota walitti qabaa jiraSadarkaa 3
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · Miili 19 fagaatti
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · Miili 19 fagaatti
- New York Cancers & Blood Specialists, Port Jefferson Station · Miili 19 fagaatti
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · Miili 4 fagaatti
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · Miili 5 fagaatti
- fi 1 dabalataa
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Namoota walitti qabaa jiraSadarkaa 2
- Stony Brook Cancer Center, Stony Brook · Miili 18 fagaatti
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Namoota walitti qabaa jiraSadarkaa 2
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · Miili 4 fagaatti
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · Miili 5 fagaatti
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- New York Cancer and Blood Specialists, Port Jefferson Station · Miili 19 fagaatti
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Stony Brook University Cancer Center, Stony Brook · Miili 18 fagaatti
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital - Fairfield, Fairfield · Miili 5 fagaatti
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · Miili 4 fagaatti
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · Miili 5 fagaatti
- Stony Brook University Medical Center, Stony Brook · Miili 18 fagaatti
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Stony Brook Medicine, Stony Brook · Miili 18 fagaatti
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Stony Brook Breast Center, Stony Brook · Miili 18 fagaatti
Definitive Radiation Therapy for Inoperable Breast Cancer
Namoota walitti qabaa jira
- Stony Brook University Cancer Center, Stony Brook · Miili 18 fagaatti
Definitive Radiation for High-Risk Spine Metastases
Namoota walitti qabaa jiraSadarkaa 2
- Stony Brook University Hospital, Stony Brook · Miili 18 fagaatti
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Namoota walitti qabaa jiraQorannoo ilaalaa
- Stony Brook University Cancer Center, Stony Brook · Miili 18 fagaatti
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Bridgeport keessatti
- Kansara Qara'a Non-Small CellQorannoo 14
- Dhibee QaraQorannoo 13
- Leukemia Myeloidii HamaaQorannoo 12
- Dhibee Onneessaa fi DhiigaQorannoo 9
- Saree (Gosoota Hunda)Qorannoo 8
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 8
- Kansara MetastatikiiQorannoo 7
- Cufama OnneeQorannoo 7
- Aneurysm SerebriiQorannoo 6
- Myeloma Baay’eeQorannoo 6
- Kansarii ProstateQorannoo 6
- Kansarii OvariiQorannoo 5
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.